Cangrelor for Cardiogenic Shock Patients
Author Information
Author(s): D’Andria Ursoleo Jacopo, Baldetti Luca, Pieri Marina, Nardelli Pasquale, Altizio Savino, Ajello Silvia, Scandroglio Anna Mara
Primary Institution: IRCCS San Raffaele Scientific Institute
Hypothesis
What is the safety and efficacy of cangrelor in patients with acute myocardial infarction and cardiogenic shock?
Conclusion
Cangrelor administration in AMI-CS patients was feasible and safe with a low rate of thromboembolic complications, but bleeding complications were more frequent.
Supporting Evidence
- Ten studies involving 678 patients were included in the review.
- Cangrelor was administered intravenously at various dosages.
- The pooled rate of major bleeding was 17%.
- The pooled rate of stent thrombosis was 1%.
- The pooled hospital survival rate was 66%.
- 26% of patients received temporary mechanical circulatory support.
- All studies reported concomitant systemic anticoagulation.
Takeaway
Cangrelor is a medicine that helps prevent blood clots in very sick heart patients, and it works well but can cause bleeding.
Methodology
A systematic review and single-arm meta-analysis of studies reporting on cangrelor use in AMI-CS patients.
Potential Biases
Potential bias due to the observational nature of most studies and lack of control groups.
Limitations
The included studies were non-randomized and heterogeneous, with small sample sizes and variable outcomes.
Participant Demographics
Patients aged 18 years or older with acute myocardial infarction and cardiogenic shock.
Statistical Information
Confidence Interval
11–23% for major bleeding, 0.3–2.3% for stent thrombosis, 0.4–7% for any thrombosis, 59–73% for hospital survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website